Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.53 |
| ▸ | TYK2 | P29597 | 2/20 | 0.53 |
| ▸ | CDK4 | P11802 | 6/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 2/20 | 0.41 |
| ▸ | CTSC | P53634 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.38 |
| ▸ | CDK9 | P50750 | 4/20 | 0.38 |
| ▸ | CCNK | O75909 | 3/20 | 0.38 |
| ▸ | CCND3 | P30281 | 3/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372541 | 0.87 | JAK2 (0.60) | JAK2TYK2WEE1TSHRSRC | |
| SCHEMBL2372556 | 0.87 | JAK2 (0.55) | JAK2TYK2CDK4CCNA2CDK2 | |
| SCHEMBL12294740 | 0.85 | TYK2 (0.71) | JAK2TYK2WEE1TSHRSRC | |
| SCHEMBL2382840 | 0.85 | TYK2 (0.49) | JAK2TYK2SRCCDK6CDK9 | |
| SCHEMBL2372700 | 0.83 | JAK2 (0.58) | JAK2TYK2WEE1SRCCYP3A4 | |
| SCHEMBL2372424 | 0.82 | TYK2 (0.50) | JAK2TYK2CDK4CCNA2CDK2 | |
| SCHEMBL2371610 | 0.80 | TYK2 (0.64) | JAK2TYK2WEE1TSHRSRC | |
| SCHEMBL12296260 | 0.77 | JAK2 (0.48) | JAK2TYK2CDK4CCNA2CDK2 | |
| SCHEMBL2372584 | 0.76 | TYK2 (0.60) | JAK2TYK2CDK4CCNA2CDK2 | |
| SCHEMBL2372667 | 0.76 | JAK2 (0.44) | JAK2TYK2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | JAK2 6/4885TYK2 1/4885CDK4 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.